Drugs / NPH insulin
NPH insulin
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00835861 | Aug 2008 → Feb 2010 | pregnancy disorder, type 2 diabetes mellitus | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00440284 | Jan → Dec 2004 | type 2 diabetes mellitus | University of Jena | Unknown | Met primary |
| Phase 47 trials · 3 missed | ||||||
| Phase 4 | NCT06999551 | Jul → Dec 2025 overdue | type 2 diabetes mellitus | Les Laboratoires des Médicaments Stériles | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03511521 | Mar 2018 → Aug 2019 | hyperglycemia | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03350984 | Nov 2017 → Jul 2018 | type 2 diabetes mellitus | University of Guanajuato | Completed | No outcome recorded |
| Phase 4 | NCT01854723 | Apr 2013 → Dec 2015 | diabetes mellitus | Providence Health & Services | Withdrawn | No outcome recorded |
| Phase 4 | NCT01810952 | Sep 2010 → Sep 2013 | diabetes mellitus, hyperglycemia | Baylor College of Medicine | Completed | Missed primary |
| Phase 4 | NCT01184014 | Aug 2010 → Aug 2012 | hyperglycemia | HealthPartners Institute | Completed | Missed primary |
| Phase 4 | NCT00941369 | Jun 2009 → Oct 2012 | type 2 diabetes mellitus | Sanofi | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT00626080 | Jan 2009 → Dec 2011 | type 1 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Comparator or background therapy24 trials | ||||||
| Phase 3 | NCT02033889 Background | Dec 2013 → Aug 2017 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT01223131 Comparator | Feb 2011 → Mar 2014 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00474045 Comparator | May 2007 → Aug 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT00115570 Background | Apr 2005 → Nov 2006 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03220425 Comparator | Feb → Nov 2001 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT04834362 Comparator | Apr → Jun 2021 | hyperglycemia, stroke disorder | National Institute of Neurosciences and Hospital, Dhaka | Completed | Missed primary |
| Phase 4 | NCT04664764 Comparator | Feb 2019 → Feb 2021 | type 1 diabetes mellitus | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT02967211 Comparator | Dec 2015 → Oct 2017 | type 2 diabetes mellitus | Sanofi | Completed | Missed primary |
| Phase 4 | NCT02967224 Comparator | Nov 2015 → Oct 2017 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Phase 4 | NCT02451917 Comparator | Dec 2013 → Aug 2016 | chronic kidney disease, type 2 diabetes mellitus | University of Sao Paulo General Hospital | Completed | Mixed |
| Phase 4 | NCT02758522 Comparator | Oct 2013 → Oct 2015 | diabetes mellitus, hyperglycemia | Hospital Universitario Dr. Jose E. Gonzalez | Completed | No outcome recorded |
| Phase 4 | NCT01683331 Comparator | Aug 2012 → Feb 2018 | — | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT01500850 Comparator | Oct 2011 → Oct 2012 | type 2 diabetes mellitus | ikfe-CRO GmbH | Unknown | No outcome recorded |
| Phase 4 | NCT01122979 Comparator | Jul 2010 → Oct 2013 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02607410 Comparator | Jan 2010 → Jan 2012 | type 2 diabetes mellitus | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00941148 Comparator | Apr 2008 → Mar 2009 | diabetes mellitus, noninsulin-dependent, 2 | ikfe-CRO GmbH | Completed | No outcome recorded |
| Phase 4 | NCT00590226 Comparator | Dec 2006 → Jan 2008 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT00841919 Comparator | Dec 2006 → Mar 2009 | type 2 diabetes mellitus | Cook County Health | Completed | Met primary |
| Phase 4 | NCT01271517 Comparator | Sep 2005 → Mar 2011 | type 1 diabetes mellitus | Karolinska Institutet | Unknown | No outcome recorded |
| Phase 4 | NCT00747409 Comparator | Jul 2004 → Mar 2009 | type 2 diabetes mellitus | Munich Municipal Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00686712 Comparator | Feb 2003 → Aug 2009 | type 2 diabetes mellitus | Charles Drew University of Medicine and Science | Completed | No outcome recorded |
| — | NCT01140438 Comparator | Mar 2009 → Nov 2018 | diabetes mellitus | Norwegian University of Science and Technology | Completed | No outcome recorded |
| — | NCT00609986 Comparator | Jul 2007 → Oct 2010 | diabetes mellitus, hyperglycemia | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT00574405 Comparator | Apr 2005 → Mar 2010 | type 1 diabetes mellitus | Arkansas Children's Hospital Research Institute | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 42 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPH insulin | “Insulin detemir is a basal insulin analog that causes less weight gain than other basal insulin formulations, including the current standard intermediate-long acting Neutral...” PMID 24739875 ↗ Apr 201433“CIT consisted of twice daily injections of premixed insulin (30% regular insulin, 70% NPH-insulin) before breakfast and dinner.” NCT00440284 ↗ “Neutral Protamine Hagedorn (NPH) Insulin Titration Regimen” NCT01683331 ↗ “Patients will receive NPH insulin in a once-daily regimen.” NCT02758522 ↗ “The NPH insulin vial is a 10 ml vial dosed at 100 IU/mL” NCT06999551 ↗ “Regular insulin and NPH insulin” NCT04834362 ↗ “NPH Insulin” NCT00835861 ↗ “NPH insulin” NCT02033889 ↗ |
| Known as | human isophane insulin | “NPH (neutral protamine Hagedorn) insulin (human isophane insulin)” PMID 33166419 ↗ Nov 2020 |
| Known as | insulin isophane | “NPH insulin (insulin isophane)” NCT01122979 ↗ |
| Known as | Insuman Basal | “Neutral Protamine Hagedorn basal insulin: Insuman® Basal (100 I.U./ml) in TactiPen® re-usable pen” NCT00941369 ↗ |
| Known as | neutral protamine Hagedorn | “Neutral Protamine Hagedorn basal insulin: Insuman® Basal (100 I.U./ml) in TactiPen® re-usable pen” NCT00941369 ↗4“The intervention is Neutral Protamine Hagedorn (NPH) insulin plus complete insulin orders (CIO).” NCT01184014 ↗ “insulin detemir versus neutral protamine Hagedorn (NPH) insulin in basal-bolus therapy” PMID 15220016 ↗ May 2004 “Neutral protamine Hagedorn (NPH) insulin was the reference therapy.” PMID 27887605 ↗ Nov 2016 “neutral protamine Hagedorn (NPH)” PMID 19017758 ↗ Nov 2008 |
| Known as | Neutral Protamine Hagedorn (NPH) | “A "coverage" dose of 0.1 unit/kg/day of Neutral Protamine Hagedorn (NPH) for each 10 mg of prednisone or its equivalent was given twice daily with the administration of the...” NCT01810952 ↗ |
| Known as | neutral protamine Hagedorn (NPH) insulin | “The purpose of this study was to compare the glycemic response to treatment with glargine U100 or neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes...” PMID 31383366 ↗ Aug 2019 |
| Known as | neutral protamine hagedorn insulin | “comparing insulin detemir with neutral protamine hagedorn insulin, both with insulin aspart, in women with type 1 diabetes planning a pregnancy (n = 306) or are already...” PMID 21557440 ↗ Sep 20111“regular insulin before meals and basal neutral protamine Hagedorn insulin twice daily (control).” PMID 21454236 ↗ Sep 2011 |
| Known as | NPH | “OBJECTIVE: This randomized, controlled noninferiority trial aimed to compare the efficacy and safety of insulin detemir (IDet) versus neutral protamine Hagedorn (NPH) (both...” PMID 22851598 ↗ Jul 20121“insulin detemir versus neutral protamine Hagedorn (NPH) insulin in basal-bolus therapy” PMID 15220016 ↗ May 2004 |
| Known as | NPH human insulin | “GROUP 2 - NPH human insulin, three applications per day” NCT02451917 ↗ |
| Modality | Protein / enzyme biologic | “human insulins” PMID 19017758 ↗ Nov 2008 |
| Route | Subcutaneous | “subcutaneous injection twice daily” NCT00115570 ↗ |